Join us at
ISPOR US 2026
The global healthcare landscape is evolving fast—are you ready to adapt?
Connect with our Evidence Enabled Experts to explore real-world strategies helping Biopharmaceutical and Medtech leaders overcome today’s toughest challenges. Stop by booth #1042 to access exclusive content, speak with our team, and see how we empower companies like yours to lead with evidence.
Alison Isherwood
Director and Head of Epidemiology
Alison is Head of Epidemiology at Clarivate, bringing over 17 years of healthcare and life sciences consultancy experience. She has deep expertise in partnering with senior industry stakeholders to address crucial business questions using diverse datasets and analytical methods. Her main areas of focus are sizing and forecasting eligible patient populations, prevalence modelling for orphan designation applications, modelling disease progression, risk-based modelling for female cancers, and diversity planning.
Stacey Chang-Douglass
Director and Head of Health Economics
Stacey is Head of Health Economics at Clarivate, where she oversees the delivery of economic modelling to support HTA submissions, global model development and country adaptations. With 15 years of health economics experience spanning positions in consulting and at NICE, she provides strategic insights and technical guidance on projects across an extensive range of therapy areas. She also serves as a standing member of NICE’s Medical Technologies Advisory Committee, a role she has held since 2022.
Chris Marshall
Director, Clinical Outcomes Assessment
Chris is a director on the Clinical Outcomes Assessment (COA) team at Clarivate with over 15 years of experience in the design and implementation of COA strategies in clinical development plans. He acts as strategic lead on COA projects including literature reviews, interview and psychometric studies, and providing support to clients for regulatory interactions. Chris has presented workshops related to the development of COA measures at both the ISPOR and ISOQOL international conferences.
John Stahl
Partner, US Pricing and Market Access
John leverages over 20 years of deep healthcare knowledge as well as a broad range of market access and commercialization experience to effectively deliver strategic and actionable insights to biopharmaceutical and medtech clients. John has been with Clarivate for 10+ years, and during this time, he has supported clients with the development of market access landscape assessments, evidence generation and value communication strategies, pricing and contracting strategies, and account engagement strategies and tactics. His experience spans numerous TAs, with a concentration in cell and gene therapy, rare disease, oncology, immunology, and neurology conditions.
Jade Seidman
Senior Manager, Value Communication
Jade is a Senior Manager at Clarivate, serving as the project manager and strategic advisor in the Value Communication team. With extensive experience guiding the development of GVD, PVS, PMR and other strategic projects, Jade leverages deep expertise to deliver actionable insights that support evidence-based decision-making. Her work spans multiple markets of interest and therapeutic areas, including oncology, endocrinology and cardiovascular indications.
Throughout her career, Jade has partnered with global pharmaceutical clients to optimize market access strategies and demonstrate product value. She combines analytical rigor with a nuanced understanding of clinical and economic data to inform critical business decisions.
James Young
Engagement Manager Real-World Data (RWD)
James is an Engagement Manager at Clarivate, serving as the client lead for custom Real World Data (RWD) projects. He has extensive experience working with medical claims, pharmacy claims, and electronic health record (EHR) data, and has led RWD engagements supporting clients across HEOR, Market Access, Commercial Operations, Marketing, Sales, Medical Affairs, and more. James has nearly 10 years of experience in healthcare and holds a Master of Public Health and a Bachelor of Science in Biomedical Physiology.
